Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment

[1]  Osama Sabri,et al.  Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios? , 2016, The Journal of Nuclear Medicine.

[2]  C. Rowe,et al.  OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETA CHANGE WITH 18F-FLORBETABEN PET , 2016, Alzheimer's & Dementia.

[3]  John Seibyl,et al.  Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study , 2016, The Journal of Nuclear Medicine.

[4]  John Seibyl,et al.  Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans , 2016, The Journal of Nuclear Medicine.

[5]  J. Schnabel,et al.  Classification of amyloid status using machine learning with histograms of oriented 3D gradients , 2016, NeuroImage: Clinical.

[6]  Osama Sabri,et al.  Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer’s disease , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  T. Montine,et al.  Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques. , 2015, JAMA neurology.

[8]  Lennart Thurfjell,et al.  The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.

[9]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[10]  C. Rowe,et al.  Amyloid imaging in therapeutic trials: The quest for the optimal reference region , 2015, Alzheimer's & Dementia.

[11]  Sterling C. Johnson,et al.  High amyloid load is associated with episodic memory decline and incident mild cognitive impairment in middle-aged adults in the wisconsin registry for Alzheimer’s prevention (WRAP) , 2015, Alzheimer's & Dementia.

[12]  C. Rowe,et al.  18F-Florbetaben (FBB) PET SUVR quantification: Which reference region? , 2015 .

[13]  M. Sabbagh,et al.  Age dependence of brain β-amyloid deposition in Down syndrome , 2015, Neurology.

[14]  Lennart Thurfjell,et al.  Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.

[15]  J. Pariente,et al.  Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  C. Rowe,et al.  18F-florbetaben Aβ imaging in mild cognitive impairment , 2013, Alzheimer's Research & Therapy.

[17]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[18]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[19]  Christian Gaser,et al.  Models of the Aging Brain Structure and Individual Decline , 2012, Front. Neuroinform..

[20]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[21]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[22]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[23]  E. S. Pearson,et al.  THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .

[24]  C. Rowe,et al.  18 F-florbetaben Ab imaging in mild cognitive impairment , 2013 .

[25]  Nick C Fox,et al.  Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. , 2011, Brain : a journal of neurology.

[26]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .